诺诚健华：港股公告：2023年中期报告
中期報告2023
InnoCare Pharma Limited
諾誠健華醫藥有限公司
（於開曼群島註冊成立的有限公司）
股份代號：
9969
19DEL19AD
ALLAMLAQP4 IgG4ARRArriVentArriVent Biopharma ASH
BBBT
BBiogenBiogen Inc.BIIB
BTDBTKBTKCD20BCD20MS4A1BCDC
CDENMPA
CLLCNSL
9969
DLBCLBDLTEGFREULARFGFRFL
GMP
IBDICP-105ICP-192ICP-022
IL-2-2IL-12-12IL-23-23IMiDIND
IRCITKTITPJAK
MCDB(DLBCL)MYD88L265P
CD79BMCDMCLBMOA
MSMZL
NDAMMOSDNMPA
NRDLNSCLCNTRKFGFR(FGFR)TRKPD
PK
R/Rr/rR-CHOPRICE
264,648,217
SC
0.000002
SHP2RASSLESLLSRISLE
TT
TBNKTDCCTTRKTYK22UC
U.S.FDAFDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII, LLCWM
Ogier Global (Cayman) Limited89 Nexus WayCamana BayGrand CaymanKY1-9009Cayman IslandsOgier Global (Cayman) Limited89 Nexus WayCamana BayGrand CaymanKY1-9009Cayman Islands
1712-1716
9969 www.innocarepharma.com
tafasitamabICP-248ICP-B02ICP-490NHLMMBDLBCL
?
?BTK
320.7217.047.8%CSCO? MZLNDA
NMPAMZLBTK
IRCORR58.9%DOR34.3(95% CI)
12PFSOS82.8%91%? CLL/SLL
IIINDA? MCLII
FDAFDANDA
? MCDDLBCL1LIII
R-CHOPR-CHOPMCDDLBCL45ICP-B04TafasitamabCD19Minjuvi
?? BDLBCL
II52CDENDANDA
tafasitamabDLBCLtafasitamabBLAASCT
DLBCLDLBCL? Tafasitamab
ASCTDLBCLTafasitamabDLBCLDLBCtafasitamab
CSCOASCTDLBCLICP-248? ICP-248B2BCL-2I
CLL/SLLMCLNHL
BCL-2PKCRuMRDCLL/SLL
IND
ICP-B02 (CM355)? CP-B02CD20xCD3I/IIICP-B02NHL
PKIVSC
IVSCICP-B02FLDLBCLICP-490
? ICP-490
MMI1DLT21CD3+TBPD
Aiolos (IKZF3)Ikaro (IKZF1)TICP-490MMICP-B05 (CM369)
? ICP-B05C-C8CCR8
(2162.HK)
IICP-B05DLTPKPDT
NHLINDBTBT
? ITPPoC
ITPIIPoC
EHA50QD40%GCIVIG
BTKITP
AIDBTK? SLEIIaSLESRI-4
IIb? MSII2412
Cmax1250QD80QD24Gd+T1
92.3%MS
4T12480QDGd+T1
24TEAEMS
ICP-332? ICP-3322TYK2T
IPKJAK-2AEAD80120QDIIII
ICP-488? ICP-488TYK2TYK2JH2IL-23
IL12IIFNICP-488ISADMADPoCI2
IIPoC
ICP-192ICP-723
ICP-189ICP-B05ICP-033
ICP-723 (Zurletrectinib)? I/IIICP-723NTRK
TRKiPKICP-723NTRK12II
ORR80%-90%ZurletrectinibTRKTRKiCDE212
IND
ICP-192 (Gunagratinib)? GunagratinibFGFR
ICCAIIASCO-GIGunagratinibIIaICP-192
ICP-189? ICP-189SHP2
IaICP-189
120QDDLTPKICP-189201
PRICP-189ArriVentfurmonertinibEGFRIND
ARRIVENT
ArriVent BiopharmaArriVentSHP2ICP-189ArriVentfurmonertinibEGFRArriVentICP-189furmonertinibNSCLCICP-189furmonertinibINDCDE
377,549245,958131,26599,292(191,208)(186,054)(358,130)(273,519)
(87,299)(78,519)(179,150)(160,544)(429,184)(445,812)
(206,261)(225,020)
(429,184)(445,812)
178,005155,04244,91865,750(206,261)(225,020)
246.053.5%
377.5
217.047.8%
320.7
99.3
131.3
59.234.693.8
698.6815.8(i)273.5358.1(ii)
264.6278.5(iii)
155.0178.0
445.8
429.2
225.0
206.3
8,688.66,518.8
9,011.2
Tafasitamab
NDA
PH3PHIaPH2*
NDA
PHIbPH2**
ICP-022/Orelabrutinib
BTK
r/rCLL/SLL20201225r/rMCL20201225
r/rMZL2023421
ICP-B02CD3xCD20
ICP-248NHL/ALL/BCL-2
ICP-490MM/DLBCL/E3 Ligase
1L : CLL/SLL
Tafa + LEN, r/rDLBCLr/rMCL
1L : MCL
ICP-B04/
Tafasitamab
CD19
IV&SC
1L : MCD DLBCL
HK
CHN,
CHN
CCR8ICP-B05
CHN2024
20242024
NDA
PH3PHIaPH2*PHIbPH2**
ICP-B05
pan-FGFR
()pan-TRKNTRK()ICP-192/GunagratinibICP-723/Zurletrectinib
VEGFR,DDR1ICP-033
SHP2ICP-189
CCR8
20232
IIPoC
BTKTYK2 –JH1
ICP-022/Orelabrutinib
ICP-332
TYK2 –JH2
/
ICP-488
+EGFRiNSCLCIND
?
BTK?
BTKCLL/SLLMCL?
CSCOCLL/SLLMCLBTKDLBCLpCNSL
377.5
320.747.8%330DOT
tafasitamabICP-248ICP-B02ICP-490NHLMMBDLBCL
NHLNM(i)(ii)FDAEMACD19tafasitamabDLBCL(iii)
BCL-2CD20xCD3E3CCR8(iv)
DLBCLtafasitamabBCL-2E3
DLBCL1L DLBCLMCDtafasitamabDLBCL
Tafasitamab
MMOthersCLL/SLLMCLMZLWMFLCNSLDLBCL
PTCL/CTCL
AMLALLCMLOthers
ICP-490
ICP-B02
Orelabrutinib
ICP-490
ICP-248
ICP-B05/
CM369
ICP-248
CLL/SLLMCLMZL
BTKAE3
MZL
MZLBNHL8.3%MZL
MZLNMPAMZLMZLBTK
ICMLMZLIRC
ORR
IV75.9%24.3IRCORR58.9%DoR34.3PFS12PFS82.8%12OS91%TRAE
MCL
MCLBBMCL
MCLCRBloodBlood AdvancesBTKMCL
MCL10646.98
CTORR83%35.8%CR3.8%CRu43.4%PR
25.7924.94OS56.21
MCLII
FDABTDMCL
1L CLL/SLL
IIICLL/SLLIRCPFSIII531L CLL
NDA1L DLBCL-MCD
DLBCLNHL100MCD1L DLBCLIIIR-CHOPR-CHOPMCDDLBCL
40%DLBCL
R-CHOP+XMCDBNF-KBBTK
TITKCD20NKADCC
R-CHOPMCDDLBCLASCOR-CHOPMCD DLBCL
14MCD DLBCL1508R-CHOPR-EPOCH6RICER-CHOPR2CRR75%66.67%
MCDDLBCL
MCDDLBCL
CLL/SLL
IICLL/SLL15080CLL/SLL
52.442.5%ORR93.8%CR30%
1.84DORPFS5250CLL/SLLBTKCR
AECLL/SLLGazyvaFCR
BTKi
7.1611.073PR/PR-LSDORR75%DCR100%BTKiCLL/CLL
1L DLBCLGCBEHAORIENT
R-CHOPBBGCBDLBCL
R-CHOPGCB DLBCL
GCB DLBCLR-CHOP
tafasitamab (CD19)ICP-B02 (CD3xCD20)ICP-490E3
DLBCL
pCNSLEHAPomalidomideMethotrexate
CNSII
pCNSLND pCNSLPomalidomideORRpCNSLpCNSL
ND pCNSLCNSLpCNSLORRCR88.9%100%53.9%61.8%NDpCNSL
PFSmPFS6PFS63.6%100%
60%CNSLORR60%86.7%mPFS9.83mPFSBCRMYD88MOABBB15021.6
BBB58.6%pCNSL
BTKCD20
BTKBBCRCD20CDCADCC/ADCPBTK2TTKLNKADCC(Mol Ther Oncolytics 21: 158-1702021
BTKBTKITKB
ADCCMol Ther Oncolytics 21:158-1702021GazyvaADCCADCP
CD20Gazyva (obinutuzumab)ADCCADCP
BTKCD20/CD19B
CD20GazyvaBTafasitamabNHLIIICP-B04 (Tafasitamab)
CSCOtafasitamabASCTDLBCL
DLBCLCHOPtafasitamab23
tafasitamabDLBCLTafasitamab
TafasitamabDLBCLII
IItafasitamabDLBCLORRIRCDCRDoRPFSTTPTTROS
6NDATafasitamabASCTDLBCLTafasitamabDLBCL
DLBCCD19B-NHLB-NHLRE-MIND2R2
tafasitamab
tafasitamab
tafasitamabtafasitamabtafasitamabNMPA
2CRtafasitamabBLAASCTDLBCL
DLBCLTafasitamabB
NHL/DLBCLtafasitamabDLBCLNHLNHL40%
ICP-248ICP-248B2BCL-2BCL-2BCL-2
BCL-2
ICP-248ICP-248BCL-2ICP-248CLL/SLLNHLDLBCLIIICP-248BCLL/SLLMCLNHL
BCL-2CRSDCLL/SLLNDAICP-B02 (CM355)ICP-B02BCD20xCD3TDCC
I/IIICP-B02IVSCNHLPKI
ICP-B025IV1SCDLT1SCDLTIVSCNHLDLBCLIVSC
ICP-490ICP-490CRBN E3IMiD
TPDCRL4CRBN-E3ICP-490IKZF1IkarosIKZF3AiolosICP-490MMBDLBCLICP-490
CRNBICP-490ADCCCD38daratumumab
AACRICP-490ICP-490MMNHLDLBCLIC50ICP-490ICP-490
ICP-490MMDLBCLICP-490ICP-490IL-2BCD38daratumumabMMNHLICP-490BTK
ICP-490MMI21CD3+ TBAiolos (IKZF3)Ikaro (IKZF1)TICP-490
ICP-490IberdomideCRBNICP-490MMNHL
ICP-B05 (CM369)ICP-B05C-C8CCR8
CCR8TME
TTregsICP-B05CCR8TregsADCCTregsTMEICP-B05T
IICP-B05
DLTPKI
ICP-B05CCR8TICP-B05NHLICP-B05NHLINDBTBT
ICP-332 (TYK2-JH1)ICP-488 (TYK2-JH2)
ADPsoriasisLNCDUCSLEMSITPNMOSDCSU
T
B
(BTK)
I/IIII
IIaIIb
IIIIIIPoCIII
MSNMOSDITPCSUSLEADLNCD
CNSBITPPoCGCIVIG
IIISLEIIaSLEBTKIIbMSIIPoCIINMOSDCSU
TTYK2ICP-332ICP-488TADSLELNCDUC
BICP-332ICP-488TB
BTKTECBBCR
BBTKBTK
ITPITPITP
TITP100,00023.6100,0009.5
CD20
BTKBITPB
BTKITPITP
ITPIIIIITPIII
×
/L27
ITPPoCEHAITPII
3350QD30QDITP50QDGCIVIG
36.4%33125040%1561283.3%121014-246
450x10
/L22GCIVIG50
75.0%86ITP
TRAE12IIITPBTKITP
BTKAID
SLE
BTKBCRB
SLESLESLE
1.060.7%SLE
1.090.5%
SLEIIaEULARSLE1:1:1:11250QD80QD100QDIIa
508010012SRI-435.7%50.0%61.5%64.3%
GC3C4
35.7%
50.0%
61.5%
64.3%
14.3%
25.8%
28.6%
(n=55)
0%10%20%30%40%50%60%70%80%90%
| 100% |
(N=14)
(N=14)
(N=13)
(N=14)
IIa40IIb
IIbSLESLESLE
1:1:1507548SRI-4SRI-4
C3C4dsNDA4850%12SLEBTKevobrutinibfenebrutinibRingheim, G. E., Wampole, M., & Oberoi, K. (2021)Frontiers in Immunology, 12, 662223SLEBTKSLE
MSICP-CL-00112IIRMS24
OLE
IIMSII2412
Cmax4T1241250QD80QD24Gd+T1
92.3%MS
24Gd+T1PHSN=115
4812162024
50QD50QD
| BID |
80QD
50QD
QD=BID=CI=Gd+ =
424Gd+T1
50QD
(N=27)
50QD
(N=30)
50BID
(N=29)
80QD(N=29)
(95% CI)
6.45 (3.62, 11.52)2.10 (0.62, 7.11)1.08 (0.30, 3.81)0.50 (0.09, 2.74)
(-22.0, 91.3)83.3 67.4 (33.2, 95.8)92.3 (56.5, 98.6)
0.09580.0114
0.0037
P
80QDGd+T124TEAEMSALT/AST>8xULN50BID50QD80QDFDA
MSDMTFDABiolato M, Bianco A,Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-RemittingMultiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs . 2021 Aug;35(8):861-880
26MS2624
HBV
DMTBiolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M,Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: ANarrative Review. CNS Drugs. 2021 Aug;35(8):861-880ALTALT
ALT
β136
136912C62C
BC
A
BMSIIMSOLE
MSBTKNMOSDNMOSD
45-650.445/100,0004.71:1BTKBBBTKBTKBTKNMOSDIITII
TTYK2ICP-332ICP-332TYK2TYK2JAKIL-12/IL-23IFN
T17TH17TH1BADICP-332
TYK2400JAK2JAKTYK2ICP-332
IBDPharma Intelligence12
0.96-22.6%1.2-17.1%100
ICP-332
IPK/PDJAK-2AE
ADIIII
I14ICP-332532040160QDPKPD8
ICP-3326280ICP-322ICP-3325320PKCmaxAUC last
IMAD
14320160QDICP-332
JAK2
II
ICP-488
ICP-488TYK2JH2JH2TYK2JH2
TYK2ICP-488TYK2TYK2 JH2IL-23IL-12IIFNICP-488SLELNIBDICP-332ICP-488TYK2I136SADMAD2
IIICP-488II
JAKICP-488
ICP-192ICP-723
ICP-189furmonertinibsNSCLC
ICP-B05ICP-033
FGFRICP-192TRKICP-723
SHP2CCR8ICP-189ICP-B05ICP-033
ICP-723 (Zurletrectinib)ICP-723TRKTRK
TRKNTRKTRKTRKICP-723
TRKA/B/CTRKAG595RG667CICP-723TRKTRKTRKATRKBTRKCNTRK1NTRK2NTRK3TRKNTRKNTRKNTRK
NTRK1218ICP-723CDE212IND
ICP-723NTRK12II
ORR80%-90%ZurletrectinibTRKTRKi
ICP-192 (Gunagratinib)
GunagratinibFGFRFGFR
7.1%
GunagratinibFGFRFGFR
GunagratinibFGFR
GunagratinibCCAIIaICP-19218CCA175.57ORR
52.9%179DCR94.1%1716mPFS6.9395% CI5.42TRAE
FGFRGunagratinibCCAFGR2
(52.9%)
II
ICP-192ICP-189
ICP-189SHP2ICP-189SHP2RAS-MAPK
PD-1SHP2ICP-189ICP-189EGFRKRASMEKPD-1ICP-189ICP-189
p-ERKDUSP6 mRNA
IaICP-189
120DLT3TRAESAEICP-189201PRICP-189PKICP-189EGFR
PD-1Ib
CDEICP-189EGFRiINDICP-189INDFDAIArriVent
ArriVent BiopharmaArriVent
SHP2ICP-189ArriVentfurmonertinibEGFR
ArriVentICP-189furmonertinibNSCLCNSCLC85%ArriVentEGFRHER220
NSCLCfurmonertinibEGFR1919DEL21(L858R)NSCLC
furmonertinibAllist PharmaceuticalsFurmonertinibICP-189ICP-033ICP-0331DDR1VEGFRICP-033ICP-033
ICP-033I
PROTACXDC
50,000GMP
NMPABTK
30,000
CMC70,381
8.05(3)
18A.0918A.11
B
3.10(1)
3.11
ICP-248ICP-B02tafasitamabICP-490MMNHL
MZL
?
BCLL/SLLMCLMCDDLBCLMCLNHL
BT
BITPIIPoCSLEIIaSLEBTK
IIbNMOSDIICSUMultiple Sclerosis International FederationMSIF280MSFrost & SullivanMS230
317BTKBMSBTKMS
MS
TICP-332ICP-488T
ADSLELNIBDBICP-332ICP-488T
ICP-192ICP-723ICP-189ICP-B05ICP-033
IND
ICP-B02ICP-B05tafasitamab
%%
321,46685.1217,07188.356,08314.928,88711.7
377,549100.0245,958100.0
246.0
377.5104.4
48.1%321.528.9
27.294.1%56.1
%%
279,33392.7179,75598.1
22,1447.33,4651.9
301,477100.0183,220100.0
183.274.5%
301.579.9%
99.3
131.3
59.234.693.8
273.5
358.1
%%
146,56140.992,93534.0117,65432.998,89936.220,8085.829,74610.928,2067.918,1776.644,90112.533,76212.3
358,130100.0273,519100.0
(i) 92.953.7146.6(ii) 98.918.8117.7(iii) 29.78.920.8(iv) 18.210.028.2(v) 33.811.144.9
78.5
87.3(i)34.839.8(ii)4.37.1(iii)2.14.2(iv)
7.411.3
%%
39,77245.634,79644.313,56815.517,34022.111,35113.012,66816.17,1178.24,2725.44,2264.82,0532.611,26512.97,3909.5
87,299100.078,519100.0
186.1
191.2(i)
68.481.3(ii)16.8
23.1
%%
76,28739.982,12044.181,28142.568,43736.810,5425.518,66410.023,09812.116,8339.1
191,208100.0186,054100.0
160.5179.2
19.4
23.7
2.1
8.8
1.4
20.3
209,269127,825104,01395,344109,48365,322321,580313,2908,367,0678,697,927
9,111,4129,299,708
5,000–129,429118,597
–4,242687,566727,55210,8857,75719,42420,1121,220,8751,197,168
2,073,1792,075,428
7,038,2337,224,280
7,038.28,367.1209.3
104.0109.5321.6
129.4687.61,220.9
192,065127,822
17,2043
209,269127,825
95.3
104.0(i)
33.63.437.0(ii)
45.06.851.8
36,96933,55751,81144,9877,73512,1477,4984,653
104,01395,344
65.3109.5
321.6
313.3
121,589111,1867,7897,3354266
129,429118,597
727.6
687.6(i)
104.198.9(ii)
57.041.7(iii)
32.621.3(iv)51.4
30.8
98,922104,05041,73457,01421,32032,5808,0547,62830,75051,391470,981459,51715,80515,372687,566727,552
5,000–19,42420,112470,981459,5171,220,8751,197,168
7,700–35,16535,439296,451287,7612,055,5961,999,997
2,000.02,055.6
286.0
286.6
653.2
715.8
284.1
279.3
41.3
38.6
11.7
9.6
28.032.8
4.44.5
8,697.98,367.1
65.3109.5127.8
209.3
8.95250,324,000
0.0000023,8832,240.4
H.10
37,548,00015%322.59
210,508,000
14.45
264,648,2170.000002
11.03
2,778.82
8,688.69,011.2
(i)(ii)
8.3
300.0
2.9%
100%19.6%18.8%
1,220.9
296.512.7
471.0158.5
400.0
12.7387.3
1,072
45942.82%17716.51%32830.60%10810.07%1,072100%
–
–
(i)(ii)(iii)
13.51B(1)
C.2.1(i)(ii)
(iii)
3.10(2)3.21
2,415.671,390.657.6%
50%1,207,835411,99887,447324,55140%*966,268696,20138,285657,91610%241,56747,3164,72542,591
2,415,6701,155,515130,4571,025,058*
(i)(ii)
Gaoling Fund L.P.YHG Investment L.P.Vivo Opportunity Fund, L.P.
210,508,000
16.33%14.04%14.45
421.023,041.44210,508,000
14.45
15.723,041.843,041.44
3,041,4401,336,9421,848,6981,192,742
2,919.07
140.252,778.82
1,494,220.61,494,220.6221,902.91,272,317.7116,146.6116,146.682,980.733,165.9273,851.4273,851.493,790.0180,061.4
60,952.360,952.318,957.941,994.4833,644.7833,644.7277,089.3556,555.4
2,778,815.62,778,815.6694,720.82,084,094.8
2410
571XV(a)XV78
(b)352(c)
(1)100,222,916
(2)
5.68%
116,839,593(
3)
6.62%
116,839,593
(4)
6.62%
8,311,1110.47%
(1) 1,764,321,452
(2) (1)Sunland BioMed Ltd79,326,827(2)
20,896,089
(3) (1)Sunny View Holdings Limited96,360,375(2)
20,479,218
(4) XV
XVXV7
XV23
(1)TMF (Cayman) Ltd.89,014,643
(2)
5.04%
GIC Private Limited97,614,645
(3)
5.53%
Vivo Capital LLC123,028,118
(4)
8.20%
Pang Kee Chan Hebert163,444,332
(5)
9.26%
HHLR Advisors, Ltd.208,671,222
(6)
11.83%
HHLR Fund, LP200,475,300
(6)
11.36%
(1) 1,764,321,452
(2) Golden Autumn Group LimitedStrausberg Group Limited47,900,27841,114,375Golden
Autumn Group LimitedStrausberg Group LimitedLakeview TrustSummit TrustTMF(Cayman) LtdLakeview TrustSummit TrustTMF (Cayman) Ltd
47,900,27841,114,375890,014,653
(3) Highbury Investment Pte Ltd42,559,355Highbury Investment Pte Ltd
Loyal Valley Capital Advantage Fund II LP45,487,484LVC Lion Fund LPLoyal Capital Advantage Fund II LPLVC Lion Fund LP9,567,806
Highbury Investment Pte LtdGIC (Ventures) PrivateLimitedGIC Special Investments Private LimitedGIC Special Investments Private LimitedGIC PrivateLimitedGIC (Ventures) Private LimitedGIC Special Investments PrivateLimitedGIC Private LimitedHighbury Investment Pte Ltd97,614,645
(4) Vivo Capital LLC(i) Vivo Opportunity Co-Invest, L.P.(ii) Vivo Capital Fund IX, L.P.(iii) Vivo Opportunity Fund, L.P.
(iv) Vivo Capital Surplus Fund VIII, L.P.(v) Vivo Capital Fund VIII, L.P.Vivo
2,699,2861,891,62724,673,08711,376,77982,387,339VivoCapital LLCVivoVivo123,028,118
(5) Hebert Pang Kee Chan163,442,332Success Growth Limited55,500,000
King Bridge Investments Limited106,807,145Golden SageInvestments Limited1,137,187Success Growth LimitedKingBridge Investments LimitedHebert Pang Kee ChanHebert Pang Kee ChanGoldenSage Investments Limited
(6) HHLR Advisors, Ltd.Hillhouse Capital Advisors, Ltd.HHLR Fund, L.P.Gaoling Fund, L.P.YHG
Investment, L.P.HillhouseHHLR Fund L.P.200,475,300HHLR Advisors, Ltd.HillhouseHillhouse
208,671,222
XV23XV336
1.
(i)(ii)(iii)2.
3.
274,586,514183,888,050
22,200,00068,498,464
15.56%10.42%
1.26%3.88%222,987,90774,092,857Golden Autumn Group LimitedStrausbergGroup Limited
Golden Autumn Group LimitedStrausberg Group LimitedLakeview TrustSummit TrustTMF (Cayman) Ltd.
(i)117,000(ii)
22,494,25051,481,607
Golden Autumn Group LimitedStrausberg Group Limited51,481,607
117,000
2.92%
(10%)
0.0000020.178
51,481,607117,0002.92%
17.07
2023
(2)(3)
2023
(1)(5)
2023
(4)
24,133,250610,0006,988,750430,250
(6)0017,324,2502018
2023 331541,863
0.1788.31
11.58
1.0472
1,424,5070454,507000970,0002015
1.0472
2,475,0000575,0000001,900,0002016
1.0472
0500,0000000500,0002018
2023 331444,1500.1788.31
11.58
1.0472
29,832,7571,110,0008,018,257430,250
(6)0022,494,250
(1)
(2)(3)
(4) 17.07(3)
(5)
(6) (i)313,250
(ii)117,000
17.07
10%10%128,916,5247.3%
128,916,524128,916,524
8,948,750
0.51%
7,209,0001,739,750
1%
120.1%
6.95
2023
2023
(1)
(2)
2023
1.
0165.0000000165.000
2023629,916,50020232026
6.9512.23
7.13
0.62%
050.000000050.0003,005,0000.19%
040.000000040.0002,404,0000.15%0255.0000000255.0000.96%2.
0465.9000000465.900
202362
28,000,59020232026 6.9512.23
7.13
1.76%
0465.9000000465.9001.76%0720.9000000720.9002.72%
(1) 20(2)
2.92%
(i)(ii)(iii)(iv)(v)
51,481,607117,000
2.92%
1,764,3210.1%
17.07
(12)1%
17.03D(1)
0.1%
0.0000020.178
092-202210
163240(2)
Ernst & Young27/F, One Taikoo Place979 King’s Road
Tel : +852 2846 9888Fax
| : +852 2868 4432 |
ey.com
80120
2410
4377,549245,958
(76,072)(62,738)
301,477183,2204131,26599,292
(191,208)(186,054)(358,130)(273,519)
(87,299)(78,519)(179,150)(160,544)
(23,707)(19,406)–(85)(2,087)(8,800)
(20,345)(1,397)
(429,184)(445,812)6––
5(429,184)(445,812)
(422,211)(441,343)(6,973)(4,469)
(429,184)(445,812)
8(0.25)(0.31)
5(429,184)(445,812)
233,692238,653
233,692238,653
(195,492)(207,159)
(188,519)(202,690)(6,973)(4,469)
(195,492)(207,159)
9715,809653,16310279,278284,103
3,1253,12538,63641,3059,62511,71232,83128,0421,079,3041,021,450
109,48365,32211209,269127,82512104,01395,34413321,580313,290148,367,0678,697,927
9,111,4129,299,70815129,429118,597
–4,242687,566727,5525,000–1810,8857,757
19,42420,112161,220,8751,197,168
2,073,1792,075,4287,038,2337,224,2808,117,5378,245,730
...
7,700–35,16535,43917296,451287,76118275,691278,203
615,007601,403
7,502,5307,644,327
192323
7,462,2547,597,078
7,462,2777,597,101
40,25347,226
7,502,5307,644,327
1919
2311,756,280(19,292)325,367(6,036)(36,313)(4,422,928)7,597,10147,2267,644,327––––––(422,211)(422,211)(6,973)(429,184)–––––233,692–233,692–233,692
–––––233,692(422,211)(188,519)(6,973)(195,492)
–––44,918–––44,918–44,918–101,138–(92,361)–––8,777–8,777
2311,857,418(19,292)277,924(6,036)197,379(4,845,139)7,462,27740,2537,502,530
1919
199,371,726(19,292)260,235(6,036)(465,758)(3,536,335)5,604,55954,3605,658,919––––––(441,343)(441,343)(4,469)(445,812)–––––238,653–238,653–238,653–––––238,653(441,343)(202,690)(4,469)(207,159)–––65,751–––65,751–65,751–38,896–(36,314)–––2,582–2,582199,410,622(19,292)289,672(6,036)(227,105)(3,977,678)5,470,20249,8915,520,093
(429,184)(445,812)
(32)85
20,3451,397178,644160,0314(93,771)(59,183)
–(754)2,0878,800
23,70719,406(8,290)(10,867)28,25511,93411,87010,1914,8505,69844,91865,751
(216,601)(233,323)
(37,766)(8,971)(81,412)(26,912)(4,854)(14,372)10,8327,422(32,650)(22,429)(4,579)(7,175)
(367,030)(305,760)
51,53937,206
(315,491)(268,554)
...
35,40832,495
5,85074,971(112,871)(141,213)1,702,80075,000
3––(131,368)–(1,126,427)
1,631,190(1,216,542)
5,62577912,700325,000A(6,010)(5,608)
(1,412)(1,269)(9,642)(13,952)
1,261304,950
1,316,960(1,180,146)
4,179,9843,237,48455,04485,286
145,551,9882,142,624
148,367,0675,961,24514(2,812,579)(3,817,436)
(2,500)(1,185)
5,551,9882,142,624
1.
Ogier Global(Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009 Cayman Islands
2.1
2.2
2.2
(a) 1
(b) 8
(c) 12
3.
(a)
322,234217,70255,31528,256
377,549245,958
(b)
1,078,6891,020,6956157551,079,3041,021,450
3.
10%
A102,86387,515B60,72240,038C55,31528,256D43,36327,348
262,263183,157
4.
377,549245,958
(a)
321,466217,071 55,31528,256 768631
377,549245,958
322,234217,702 55,31528,256
377,549245,958
322,234217,702 55,31528,256
377,549245,958
4.
(b)
3090
29,20128,47893,77159,183–7548,29010,867
131,26599,292
5.
28,25513,08511,87010,1912,6692,15823,70719,40644,91865,751251,066205,358337,322243,77376,07262,738178,644160,031
6.
6.
16.5%16.5%2,000,0002,000,000
8.25%8.25%16.5%16. 5%
25%15%
15%15%
50,000,00025%25%50,000,00030%30%
21%21%
7.
8.
(422,211)(441,343)
1,684,8831,411,655
9.
90,900,00083,996,000
4,00010.
62,71973,280135,9999,542163,368172,910(20,065)(4,810)(24,875)69–6952,265231,838284,103
8,662–8,662(11,098)(2,405)(13,503)
16–1649,845229,433279,278
i. 6,640
1,650
11.
195,431127,95713,938–
(100)(132)
209,269127,825
178,127127,822
17,2043195,331127,825
11.
13231
(32)100
–1100132
195,4310.05%100
127,9570.10%132
12.
36,96933,55751,81144,9877,73512,1477,4984,653104,01395,344
13.
321,580313,290 ––
321,580313,290
14.
8,367,0678,697,927(2,812,579)(4,515,379) (2,500)(2,564)
5,551,9884,179,984
5,364,0453,947,918 173,201215,970 14,74216,096
5,551,9884,179,984
15.
121,589111,186
7,7897,3354266
129,429118,597
16.
1,220,8751,197,168
1,200,564
(3,396)1,197,16823,7071,220,875
16.
6.5%
17.
287,76137,6939,265250,627
(575)(559)
296,451287,761
50,000,000325,000,0000.35%
18.
10,8857,757 275,691278,203
286,576285,960
285,960136,258
16,223197,062(14,952)(46,051)
(655)(1,309)
286,576285,960
19.
50,000500,000,000
0.000125,000,000,0000.000002
1,764,321,452 1,764,321,4522323
1,409,849199,371,726A264,64842,919,066
––(149,902)––(453,239)7,713–68,629
1,682,2102311,756,2808,018–101,138
1,690,2282311,857,418
a) 74,092,86182,111,118
20.
H
AAA0.000002AB0.000002B
10183,888,050B
1022,200,000B
20.
1068,498,464B
10%10%
20.
0.143329,8330.126137,571
0.17801,1100.17801,920
0.1780(430)0.1780(1,000)
0.1591(8,018)0.0928(4,276)
0.138722,4950.131734,215
1.04721.3626
2,7700.0000026-9-18 1-8-291,9000.05516-3-22 15-9-3117,8250.1782-8-20 30-3-3322,495
20.
6,3060.0000026-9-18 15-9-312,4750.05516-3-22 15-9-3125,4340.1782-8-20 27-4-3234,215
(%)66.0442.68-46.53
(%)3.64-4.532.19-2.83
1010H1.071.27-1.36
43.1
65.8
A
72A8,948,7500.51%A
A5.496.53
1.8
20.
Black-Scholes
(%)30.63-35.68(%)1.97-2.33
2-5A12.28
A
––
6.957,209
6.957,209
7,2096.9515
21.
139,145130,956
BTK
BTKBTK(1)
(2)BTKBTK
BTK
22.
(a)
12,36611,87417616519,68630,17232,22842,211
(b)
*
*
22.
(c)
(i)485207
485207
(ii)78107
(i)(ii)(iii)(iv)
22.
(d)
53134
53134
602117602117
23.
209,269–209,269
–321,580321,580
59,309–59,3098,367,067–8,367,0678,635,645321,5808,957,225
129,429–129,429296,451–296,451624,512–624,512
12,700–12,700–1,220,8751,220,8751,063,0921,220,8752,283,967
23.
127,825–127,825
–313,290313,290
49,640–49,6408,697,927–8,697,9278,875,392313,2909,188,682
118,597–118,597287,761–287,761637,959–637,959
–1,197,1681,197,1681,044,3171,197,1682,241,485
24.
24.
–321,580–321,580
–313,290–313,290
24.
––1,220,8751,220,875
––1,197,1681,197,168
24.
(i)
(%)1,220,8751.86~4.01
1,197,1682.15~4.30
24.
1.86%
1%(5,853)5,939
2.15%
1%(11,430)11,652
2.15%
1%(4,563)4,630
2.15%
1%(8,533)8,698
25.
1,152,00050%
50%100%